Stock 74C CROSSJECT
Add to a list
To use this feature you must be a member
Log inSign up

Crossject Stock Deutsche Boerse AG

Equities

74C

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG
Other stock markets
 02:02:11 2024-07-16 EDT 		5-day change 1st Jan Change
1.826 EUR +2.70% Intraday chart for Crossject +16.16% -59.78%
07-10 Markets Powered by Alternating Current Our Logo
07-10 Crossject Gets EUR7 Million Public Funding for New Epinephrine Product MT

Financials

Sales 2024 * 8.1M 8.83M 12.07M Sales 2025 * 53M 57.77M 79M Capitalization 84.68M 92.3M 126M
Net income 2024 * -10M -10.9M -14.91M Net income 2025 * 22M 23.98M 32.79M EV / Sales 2024 * 13.1 x
Net Debt 2024 * 21.7M 23.65M 32.35M Net Debt 2025 * 5.1M 5.56M 7.6M EV / Sales 2025 * 1.69 x
P/E ratio 2024 *
-8.24 x
P/E ratio 2025 *
3.96 x
Employees 105
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.12%
More Fundamentals * Assessed data

Chart Crossject

Dynamic Chart

Latest news about Crossject

Markets Powered by Alternating Current Our Logo
Crossject Gets EUR7 Million Public Funding for New Epinephrine Product MT
Crossject: public financing secured until 2026 CF
Crossject Receives EUR 6.9 Million Public Funding from the French Government, as Part of the France 2030 Innovation Plan, to Accelerate the Development of ZENEO Epinephrine CI
Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America CI
Crossject: successful capital increase CF
CROSSJECT : Success of the capital increase AL
Crossject Raises EUR8 Million via Rights Offering MT
Crossject Société Anonyme announced that it has received ?7.999999 million in funding CI
Crossject: capital increase until May 30 CF
Crossject: praised for extended agreement on Zepizure CF
Crossject Signs A Geographic Extension of ZEPIZURE Commercialization Agreement in Europe CI
CROSSJECT : We welcome the securing of the group’s financial needs AL
CROSSJECT : Patience is a virtue… hopefully AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
More news

Analyst Recommendations on Crossject

CROSSJECT : Success of the capital increase AL
CROSSJECT : We welcome the securing of the group’s financial needs AL
CROSSJECT : Patience is a virtue… hopefully AL
CROSSJECT : Invest Securities slightly reduces its target CF
CROSSJECT : Securing the financing needs AL
More recommendations

Press releases Crossject

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference GL
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine GL
Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study AQ
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study GL
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America GL
More press releases

News in other languages on Crossject

Crossject participera à la 26ème Annual Global Investment Conference de H.C. Wainwright
Crossject : financement public sécurisé jusqu'en 2026
En Direct des Marchés : BNP Paribas, TotalEnergies, Vallourec, Accenture, Boeing, Microsoft, Volkswagen...
Les marchés branchés sur courant alternatif
Borsa di Italia: Mercati collegati alla corrente alternata
More news

Quotes and Performance

1 day+2.70%
1 week+16.16%
Current month+12.72%
1 month+5.18%
3 months-4.40%
6 months-66.31%
Current year-59.78%
More quotes

Highs and lows

1 week
1.78
Extreme 1.778
1.83
1 month
1.43
Extreme 1.43
1.85
Current year
1.43
Extreme 1.43
5.76
1 year
1.43
Extreme 1.43
5.76
3 years
1.43
Extreme 1.43
5.76
5 years
1.09
Extreme 1.09
5.76
10 years
1.05
Extreme 1.048
10.92
More quotes

Managers and Directors - Crossject

Managers TitleAgeSince
Patrick Alexandre CEO
 Chief Executive Officer 61 01-08-07
Olivier Giré PRN
 Corporate Officer/Principal - 15-12-31
Isabelle Liebschütz LAW
 General Counsel - 12-12-31
Members of the board TitleAgeSince
Daniel Teper BRD
 Director/Board Member 64 23-06-06
Eric Nemeth BRD
 Director/Board Member 65 -
Philippe Monnot CHM
 Chairman 65 -
More insiders

Quotes

Date Price Change
24-07-16 1.826 +2.70%
24-07-15 1.778 -0.11%
24-07-12 1.78 -0.45%
24-07-11 1.788 -3.35%
24-07-10 1.85 +17.68%

Delayed Quote Deutsche Boerse AG, July 16, 2024 at 02:02 am

More quotes

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-09-08 - H.C. Wainwright Global Investment Conference
More about the company

Income Statement Evolution

More financial data

Ratings for Crossject

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.978 EUR
Average target price
4.3 EUR
Spread / Average Target
+117.39%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Drug Delivery Systems

1st Jan change Capi.
SEDANA MEDICAL AB Stock Sedana Medical AB
+15.50% 261M
Drug Delivery Systems
  1. Stock Market
  2. Equities
  3. ALCJ Stock
  4. 74C Stock